Advancements in RNA Therapeutics for Familial Chylomicronemia Syndrome

The 2026 medical landscape has introduced transformative advancements in managing *severe hypertriglyceridemia (sHTG)* and *familial chylomicronemia syndrome (FCS)* through the release of updated *ACC/AHA/Multisociety guidelines**. These new standards restore **LDL-C treatment goals* and emphasize the importance of lifelong lipid management to prevent *acute pancreatitis* and *cardiovascular disease**. Central to this shift is the approval of two innovative RNA-targeted therapies: **olezarsen (Tryngolza)**, a monthly antisense oligonucleotide, and **plozasiran (Redemplo)**, a quarterly small interfering RNA. Both drugs target the **ApoC-III protein* to significantly lower triglycerides, offering clinical efficacy even when traditional treatments fail. Research indicates that these medications can reduce the risk of life-threatening pancreatic inflammation by over *80%**. Clinicians are now encouraged to utilize these genetic-silencing tools alongside **strict low-fat diets* and multidisciplinary care to optimize patient outcomes.